How to Choose a CDMO: A 2026 Selection Checklist for Pharma Sourcing Teams

Selecting a Contract Development and Manufacturing Organization (CDMO) is one of the highest-stakes decisions a pharma or biotech team makes. The right partner compresses your timeline and de-risks your supply chain; the wrong one introduces quality failures, regulatory exposure, and months of costly tech transfer rework.

This checklist breaks the selection process into the six stages experienced sourcing teams actually use.

1. Define the requirement before you look at vendors

Before shortlisting anyone, write down the non-negotiables:

Modality and dosage form — small molecule API, biologic, sterile injectable, oral solid dose, ADC, cell/gene therapy.
Stage — preclinical, clinical trial material (CTM), or commercial-scale manufacturing.
Volume and capacity — current need plus realistic 3-year projection.
Geography — regional preferences driven by lead times, tariffs, and "friend-shoring" strategy.
Regulatory market — FDA, EMA, MHRA, or multi-region filing requirements.

A vendor that is excellent for Phase I CTM may be the wrong choice for commercial supply. Match the partner to the stage, not just the molecule.

2. Build a capability-matched shortlist

Cast a wide net, then filter against your requirement. A searchable CDMO and supplier directory lets you filter by company type, geography, and therapeutic focus in minutes rather than weeks of manual research. Many teams also narrow by region early — for example, comparing manufacturers in India against those in the United States or Germany to balance cost, lead time, and regulatory familiarity.

Aim for a shortlist of 5–8 candidates before deeper diligence.

3. Screen for FDA compliance history — early

This is the step most teams do too late. A CDMO's regulatory track record is a leading indicator of quality-system maturity. Before you invest in site visits or RFIs, screen each candidate against:

FDA Form 483 observations — issued after inspections; a pattern of repeat observations is a red flag.
Warning Letters — escalations indicating the FDA was not satisfied with a firm's response to 483s.
Recalls — especially Class I and II, which signal serious quality failures.

If you are unsure how these documents differ or how seriously to weight them, see our guide on Form 483s, Warning Letters, and recalls. Screening compliance history before the RFI stage saves you from advancing a partner you would later have to reject.

4. Run a structured RFI

Send every shortlisted vendor the same Request for Information so responses are comparable. A strong CDMO RFI covers:

Capacity, equipment, and available capacity windows
Quality systems, certifications, and recent inspection outcomes
Tech-transfer process and typical timelines
Analytical and stability testing capabilities
Capacity for scale-up and commercial supply continuity
Financial stability and ownership structure

Score responses on a consistent rubric rather than reacting to whichever sales team is most polished.

5. Weight the qualitative factors

Numbers don't capture everything. Assess:

Communication and responsiveness during the RFI itself — it predicts the relationship.
Cultural and time-zone fit for your team.
Flexibility on minimum order quantities and change requests.
Transparency about problems, not just capabilities.

6. Score, decide, and document

Combine your quantitative rubric and qualitative assessment into a single decision matrix, then document why you selected the winner. This audit trail matters for internal governance and for future re-qualification.

A faster path

The manual version of this process can take a quarter. Platforms like PharmaTek compress it by combining a searchable supplier directory with built-in FDA compliance screening and structured RFI workflows — so you reach a defensible decision in days. Book a demo to see the full workflow.